Group 1 - The new Vice President Chen Lei comes from Shanghai Pudong Development Bank, where he held various leadership positions [3][4] - Chen Lei's appointment was approved by the board of Shanghai Bank in August, and he has participated in activities related to pension finance and rural revitalization [3] - Shanghai Bank reported a revenue of 41.14 billion yuan for the first three quarters, a year-on-year increase of 4.04%, and a net profit attributable to shareholders of 18.08 billion yuan, up 2.77% [3] Group 2 - The retail business of Shanghai Bank is characterized by its focus on pension services, with retail customers reaching 21.50 million and managing a total asset under management (AUM) of 1,078.15 billion yuan, a 5.50% increase from the end of the previous year [3] - The AUM for long-tail customers increased by 50.48 billion yuan, representing a growth rate of 32.18% [3] - The AUM for pension clients reached 523.59 billion yuan, with a growth rate of 6.21%, accounting for 48.56% of the retail customer AUM, an increase of 0.32 percentage points from the end of the previous year [5]

Core Viewpoint - The announcements detail the resignation of a non-executive director and the approval of a senior management appointment, indicating ongoing governance changes within the company. Group 1: Director Resignation - The company received a resignation letter from non-executive director Mr. Gu Jingshan due to age reasons, effective from December 4, 2025 [2] - Mr. Gu confirmed there were no disagreements with the board and no other matters to notify shareholders or creditors [3] - The resignation will not impact the board's operations or the company's management, and Mr. Gu has completed the necessary handover [3] - The board expressed gratitude for Mr. Gu's contributions during his tenure [4] Group 2: Senior Management Appointment - The company received approval from the Shanghai Regulatory Bureau of the National Financial Supervision Administration for Mr. Chen Lei's appointment as vice president [6] - Mr. Chen's resume was previously published on the Shanghai Stock Exchange website on August 29, 2025 [6]

Core Viewpoints - The banking sector is expected to return to a fundamental narrative in 2026, supported by policy financial tools and resilient asset expansion, with net interest margins likely stabilizing and improving due to the ongoing deposit repricing cycle [3][9] - The report highlights two main investment lines: high-quality small and medium-sized banks with solid fundamentals and state-owned large banks with good defensive value [3][9] Group 1: Fiscal Policy and Social Financing - In 2026, fiscal policy will remain key to stabilizing demand, with a stable growth rate of social financing expected between 8.3% and 9.0% [9][41] - The fiscal deficit rate is projected to remain at least at the 2025 level, with a focus on stimulating total demand and influencing the growth rate of bank asset expansion [26][41] - The government has introduced a new policy financial tool of 500 billion yuan, which is expected to leverage a total investment scale of approximately 7 trillion yuan, with a significant portion of related loans anticipated to materialize in 2026 [26][41] Group 2: Net Interest Margin Outlook - The net interest margin for banks is expected to stabilize and improve in 2026, primarily driven by a significant reduction in liability costs, with a projected improvement of approximately 30 basis points [9][49] - The scale of deposits entering the repricing cycle in 2026 is estimated at around 112 trillion yuan, contributing approximately 17.5 basis points to the improvement in the cost of interest-bearing liabilities [47][49] - The report anticipates that the overall improvement in the cost of interest-bearing liabilities will be around 30 basis points, with a corresponding effect on net interest margins of approximately 27 basis points [49] Group 3: Non-Interest Income and Asset Quality - Growth in non-interest income is expected to return to normal levels, with a marginal decline in contributions from other non-interest income sources [9][45] - The overall asset quality is projected to remain stable, with a focus on the risks associated with individual loans and real estate loans, which are expected to be manageable [9][45] - The report indicates that corporate asset quality continues to improve, while risks in the real estate sector are expected to be controllable [9][45] Group 4: Capital and Refinancing Outlook - The capital adequacy ratios of commercial banks are expected to remain stable, with a slight decline due to fluctuations in bond market interest rates [9][45] - The successful capital injection into four major state-owned banks is anticipated to enhance their ability to manage risks and support credit issuance [9][45] - The report notes that the path for capital replenishment through external channels remains relatively blocked, particularly for small and medium-sized banks [9][45]

12月4日，上海银行（601229）发布公告称，近日该行收到《国家金融监督管理总局上海监管局关于陈雷上海银行股份有限公司副 行长任职资格的批复》（沪金复〔2025〕764 号），国家金融监督管理总局上海监管局已核准陈雷副行长的任职资格。 （上海银行） ...

【导读】上海银行新添一位副行长，此前曾任浦发银行总行零售业务部总经理 中国基金报记者 马嘉昕 12月4日，上海银行发布公告称，该行于近日收到国家金融监督管理总局上海监管局的行政批复，陈雷 出任该行副行长的任职资格已经获得核准。 新副行长系浦发"老将" 今年8月28日，上海银行曾发布公告称，该行决定聘任陈雷为副行长，任期与第六届董事会任期一致。 时隔3个月后，陈雷正式出任上海银行副行长一职。 公开资料显示，陈雷出生于1978年5月，毕业于上海交通大学工商管理专业，工商管理硕士，经济师、 政工师；2000年7月参加工作，就职于浦发银行。 从过往履历来看，陈雷从浦发银行基层一路成长起来，曾任浦发银行陆家嘴支行主办科员、市场部见习 经理，张江支行市场科科长，上海市政府驻西藏办事处业务处业务员（正科级）（挂职），总行团委书 记，上海自贸试验区分行党委委员、副行长，天津分行党委委员、纪委书记、副行长，上海分行党委委 员、副行长，宁波分行党委书记、行长，浦发银行总行直属党委委员、总行零售业务部（消费者权益保 护部）总经理。 2024年12月，陈雷还获选上海国际信托董事，并于2025年3月获准出任相关职务。据悉，浦发银行为该 ...

【导读】上海银行新添一位副行长，此前曾任浦发银行总行零售业务部总经理 12月4日，上海银行发布公告称，该行于近日收到国家金融监督管理总局上海监管局的行政批复，陈雷 出任该行副行长的任职资格已经获得核准。 新副行长系浦发"老将" 今年8月28日，上海银行曾发布公告称，该行决定聘任陈雷为副行长，任期与第六届董事会任期一致。 时隔3个月后，陈雷正式出任上海银行副行长一职。 公开资料显示，陈雷出生于1978年5月，毕业于上海交通大学工商管理专业，工商管理硕士，经济师、 政工师；2000年7月参加工作，就职于浦发银行。 从过往履历来看，陈雷从浦发银行基层一路成长起来，曾任浦发银行陆家嘴支行主办科员、市场部见习 经理，张江支行市场科科长，上海市政府驻西藏办事处业务处业务员（正科级）（挂职），总行团委书 记，上海自贸试验区分行党委委员、副行长，天津分行党委委员、纪委书记、副行长，上海分行党委委 员、副行长，宁波分行党委书记、行长，浦发银行总行直属党委委员、总行零售业务部（消费者权益保 护部）总经理。 2024年12月，陈雷还获选上海国际信托董事，并于2025年3月获准出任相关职务。据悉，浦发银行为该 信托第一大股东，截至去 ...

【 导读 】 上海银行新添一位副行长，此前曾任浦发银行总行零售业务部总经理 中国基金报记者 马嘉昕 今年以来，上海银行的核心高管经历了多轮重要调整。 5月16日，上海银行"老将"顾建忠回归，被选举为上海银行新一届董事长，其任职资格8月正式获得监管核准。在此之前，顾建忠曾任上海 农商银行行长。 5月21日，上海银行原副行长汪明因组织调动原因辞任，随后任上海农商银行行长。 随着此次陈雷任职资格获批，上海银行高管团队也迎来了"一正三副"格局，分别为董事长顾建忠，行长施红敏，副行长胡德斌、俞敏华、 陈雷。 12月4日，上海银行发布公告称，该行于近日收到国家金融监督管理总局上海监管局的行政批复，陈雷出任该行副行长的任职资格已经获得 核准。 新副行长系浦发"老将" 今年8月28日，上海银行曾发布公告称，该行决定聘任陈雷为副行长，任期与第六届董事会任期一致。时隔3个月后，陈雷正式出任上海银 行副行长一职。 公开资料显示，陈雷出生于1978年5月，毕业于上海交通大学工商管理专业，工商管理硕士，经济师、政工师；2000年7月参加工作，就 职于浦发银行。 从过往履历来看，陈雷从浦发银行基层一路成长起来，曾任浦发银行陆家嘴支行主办 ...

Group 1 - China Pacific Insurance has received approval from the financial regulatory authority for Wang Yuhua to serve as a director [1] - Shanghai Bank announced that the regulatory authority has approved Chen Lei's qualification as vice president [2] - Shanghai HuGong has decided to terminate the "Aerospace Equipment Manufacturing Base" fundraising project due to significant changes in project feasibility [3] Group 2 - Dongwang Times plans to reduce its stake by up to 1.20% through share sales [4] - Zhinancun intends to increase its capital by 100 million yuan in its wholly-owned subsidiary, Maigao Securities [5] - Jinxinnong reported a sales revenue of 115 million yuan from pig sales in November [6] Group 3 - Tiantan Biological has completed the Phase III clinical trial of its human prothrombin complex, showing good efficacy and safety for hemophilia B patients [7] - Beijete's subsidiary has signed a framework agreement for equity acquisition to gain control of Yunnan Wenye Nonferrous Metals [8] - Zhongsheng Pharmaceutical's RAY1225 injection has received approval for a new clinical trial indication for treating metabolic-associated fatty liver disease [9] Group 4 - Enhua Pharmaceutical's hydrochloride sulpiride tablets have passed the consistency evaluation for generic drugs [10] - Shenkong Co. plans to invest 60 million yuan in a semiconductor industry fund [11] - Lianhuan Pharmaceutical's subsidiary has received approval for its drug to pass the consistency evaluation for generic drugs [12] Group 5 - Dazhong Transportation has received approval to issue debt financing tools totaling 4.5 billion yuan [13] - Jintian Titanium Industry plans to invest 50 million yuan in an industry merger and acquisition fund [14] - Changchun Gas has committed over 1.7 billion yuan to gas facility upgrades [15] Group 6 - Laimei Pharmaceutical's innovative anti-cancer drug "Nano Carbon Iron" has received approval for clinical trials [16] - Longquan Co. has signed supply contracts worth approximately 50.76 million yuan for nuclear power components [17] - Igor plans to distribute a cash dividend of 1 yuan per 10 shares [18] Group 7 - Xingfa Group's subsidiary has signed a processing agreement for 80,000 tons of lithium iron phosphate [20] - Yunjigroup's director Wang Wanfeng has resigned for personal reasons [21] - Saiseng Pharmaceutical's application for the listing of a new drug has been accepted by the regulatory authority [22] Group 8 - Xinhua Medical has obtained registration certificates for two new medical devices [23] - Chaoying Electronics plans to invest 100 million USD in its Thai subsidiary for an AI circuit board expansion project [24] - Suzhou Planning's application to acquire 100% of Dongjin Aviation has been accepted by the Shenzhen Stock Exchange [25]

格隆汇12月4日丨上海银行(601229.SH)公布，近日，公司董事会收到非执行董事顾金山先生辞呈。顾金 山先生因年龄原因，向公司董事会申请辞去非执行董事、董事会战略委员会委员、董事会提名与薪酬委 员会委员职务。顾金山先生的辞任自2025年12月4日起生效。 ...

截至发稿，上海银行市值为1415亿元。 每经头条（nbdtoutiao）——让"铁疙瘩"从数万米高空精准"踩刹车"，中国商业航天"降本复用"只差"最 后一公里"！朱雀之后，同行排队接力 （记者 曾健辉） 每经AI快讯，上海银行（SH 601229，收盘价：9.96元）12月4日晚间发布公告称，顾金山先生因年龄原 因，向公司董事会申请辞去非执行董事、董事会战略委员会委员、董事会提名与薪酬委员会委员职务。 顾金山先生确认与公司董事会无不同意见，亦没有任何其他事项需要通知公司股东或债权人。 2025年1至6月份，上海银行的营业收入构成为：利息收入占比151.4%，非利息收入占比8.4%。 ...